Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study

Table 4 Multivariate analysis for overall survival

Characteristics	HR 95% CI	P value
Age, years (> 70:≤70)		0.279
Gender (female: male)		0.575
KPS (≥80:<80)	0.463 (0.269–0.796)	0.005*
Pathology (ADE:SCC)		0.374
TNM stage (IIIB:IIIA)		0.803
PET staging (yes:no)		0.836
PTV (>535 cc:≤535 cc)	1.627 (1.184–2.237)	0.003*
Concurrent chemoradiotherapy (yes:no)	0.48 (0.348–0.660)	< 0.001*
SIB-IMRT (yes:no)		0.504
RT dose (>59Gy: ≤59Gy)		0.595

KPS Karnofsky performance score, ADE Adenocarcinoma, SCC Squamous cell carcinoma, TNM Tumor-node-metastasis, PET Positron emission tomography, PTV Planning target volume, RT Radiotherapy
*p<0.05 was considered significant

ISSN: 1748-717X